Latest News - Zoetis
Top Corporates Hub
Zoetis
Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
29.10.2025 12:30
PARSIPPANY, N.J., October 29, 2025--Portela becomes first mAb therapy with a three-month dosing interval approved for the alleviation of pain associated with OA in cats.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
27.10.2025 15:40
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
21.10.2025 13:00
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why Zoetis (ZTS) Remains a Reliable Choice for Investors Seeking Profitable Dividend Stocks
08.10.2025 06:00
Zoetis Inc. (NYSE:ZTS) is included among the 13 Most Profitable Dividend Stocks to Buy Right Now. Zoetis Inc. (NYSE:ZTS) offers a range of drugs and healthcare products for companion animals and livestock worldwide. The company keeps innovating with a portfolio that includes seven main product categories and about 300 product lines. As younger generations show […]
Pet Pain For Investor Gain
26.09.2025 10:19
Discover insights on ZTS's growth driven by companion animal care and OA pain solutions.
2 Oversold Stocks Primed to Rebound and 1 Facing Challenges
26.09.2025 04:37
The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Zoetis to Host Webcast and Conference Call on Third Quarter 2025 Financial Results
23.09.2025 12:30
PARSIPPANY, N.J., September 23, 2025--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, November 4, 2025. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review third quarter 2025 financial results and respond to questions from financial analysts during the call.
Zoetis Receives Positive Opinion from CVMP for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats
12.09.2025 17:09
PARSIPPANY, N.J., September 12, 2025--If approved, Zoetis' Portela will be the first long-acting anti-NGF mAb therapy for cats and is designed to provide 3 months of OA pain relief.
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
12.09.2025 16:40
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis Inc. (ZTS) Secures a New Five-Year $1.25 Billion Senior Unsecured Revolving Credit Facility
12.09.2025 16:12
Zoetis Inc. (NYSE:ZTS) is one of the 11 Best Roth IRA Stocks to Invest in Now. Zoetis Inc. (NYSE:ZTS) strengthened its financial flexibility on August 27, 2025, by securing a new five-year, $1.25 billion senior unsecured revolving credit facility. The agreement replaces a 2022 facility that would have expired in 2027. The agreement was administered […]
Zoetis Inc. (ZTS) Reports $2.5B Q2 Revenue, Raises Full-Year Outlook on Strong Pet Care Demand
02.09.2025 08:28
We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Zoetis Inc. is one of them. Zoetis Inc. (NYSE:ZTS), a New Jersey–based global leader in animal health, continues to strengthen its position in the industry with medicines and vaccines for both companion animals and livestock. The company is […]
Zoetis: A Solid Dividend Growth Investment For The Long Haul
01.09.2025 04:14
Zoetis leads in animal health with strong growth, innovation, and safe, fast-growing dividendsânow trading near fair value. Learn why ZTS stock is a buy.
SDZNY or ZTS: Which Is the Better Value Stock Right Now?
27.08.2025 15:40
SDZNY vs. ZTS: Which Stock Is the Better Value Option?
Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
27.08.2025 12:30
PARSIPPANY, N.J., August 27, 2025--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8 at 1:05 p.m. ET.
2 Reasons to Watch ZTS and 1 to Stay Cautious
25.08.2025 04:03
Over the past six months, Zoetis’s shares (currently trading at $156.80) have posted a disappointing 7% loss, well below the S&P 500’s 8.6% gain. This might have investors contemplating their next move.
Does Zoetis Offer Value for Investors After Its Recent Rebound in 2025?
21.08.2025 10:23
If you’re on the fence about Zoetis stock, you’re definitely not alone. As the global leader in animal health, Zoetis is often on radar screens of investors searching for a slice of growth and stability. However, recent price swings have left both the bulls and the bears second-guessing their next move. In just the last month, Zoetis has managed a 6.4% gain, recovering some lost ground after sliding over the past year. The stock is still down nearly 13% over the trailing twelve months,...
[Latest] Global Canine Orthopedics Market Size/Share Worth USD 945.2 Million by 2034 at a 8.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
13.08.2025 04:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Canine Orthopedics Market size & share revenue was valued at approximately USD 420.2 Million in 2024 and is expected to reach USD 454.6 Million in 2025 and is expected to reach around USD 945.2 Million by 2034, at a CAGR of 8.6% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are B. Braun Melsungen AG, Movo
ZTS Q2 Deep Dive: Market Questions Librela Outlook Amid Double-Digit Growth in Core Franchises
13.08.2025 04:19
Animal health company Zoetis (NYSE:ZTS) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company expects the full year’s revenue to be around $9.53 billion, close to analysts’ estimates. Its non-GAAP profit of $1.76 per share was 9.2% above analysts’ consensus estimates.
5 Revealing Analyst Questions From Zoetis’s Q2 Earnings Call
13.08.2025 04:02
Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded negatively, reflecting skepticism over the company’s performance trajectory. Management highlighted robust operational growth across its Companion Animal and Livestock segments, crediting strong execution in the Simparica and Key Dermatology franchises as major contributors. CEO Kristin Peck emphasized the enduring strength of Zoetis’ diversified portfolio despite competitive press